ROS1 and non-small cell lung carcinoma: Second and third generations of TKIs have been used successfully to circumvent target mutation-associated resistance to earlier generations of EGFR, ALK, or ROS1 TKIs in non-small cell lung cancer (NSCLC)1–3.